792936-53-9Relevant articles and documents
TYK2 INHIBITORS AND USES THEREOF
-
Paragraph 00376; 00686, (2020/09/27)
Described herein are compounds that are useful in treating a TYK2-mediated disorder. In some embodiments, the TYK2-mediated disorder is an autoimmune disorder, an inflammatory disorder, a proliferative disorder, an endocrine disorder, a neurological disorder, or a disorder associated with transplantation.
ANTIDEPRESSANT HETEROARYL DERIVATIVES OF HETEROCYCLE-FUSED BENZODIOXANS
-
Page/Page column 140-141, (2009/01/24)
The invention provides compounds of the Formula: (I) that are useful for the treatment of depression (including but not limited to major depressive disorder, childhood depression and dysthymia), anxiety, panic disorder, post-traumatic stress disorder, premenstrual dysphoric disorder (also known as pre- menstrual syndrome), attention deficit disorder (with and without hyperactivity), obsessive compulsive disorder, social anxiety disorder, generalized anxiety disorder, obesity, eating disorders such as anorexia nervosa, bulimia nervosa, vasomotor flushing, cocaine and alcohol addiction, sexual dysfunction and related illnesses. The compounds are able to block the recptake of serotonin and are modulators at brain 5HT1A serotonin receptors.
3,4-Dihydro-2H-benzoxazinones as dual-acting 5-HT1A receptor antagonists and serotonin reuptake inhibitors
Lovell, Peter J.,Blaney, Frank E.,Goodacre, Caroline J.,Scott, Claire M.,Smith, Paul W.,Starr, Kathryn R.,Thewlis, Kevin M.,Vong, Antonio K.K.,Ward, Simon E.,Watson, Jeannette M.
, p. 1033 - 1036 (2007/10/03)
Investigation of halogen substitution in lead compound 1 has led to the identification of analogues which combine high affinity for 5-HT1A receptors and potent serotonin reuptake inhibitory activity. Several compounds show an improved selectivity over 5-HT1B and 5-HT1D receptors and a superior pharmacokinetic profile in the rat.
BENZOXAZINONE DERIVATIVES, THEIR PREPARATION AND USE
-
Page 9, (2010/02/09)
Compounds of formula (I) and pharmaceutically acceptable salts thereof are disclosed, wherein R1 is hydrogen or C1-6alkyl; and R2 is fluoro or chloro. Methods of preparation and uses thereof in treatment of CNS disorders, such as depression or
